Dr. Patterson was recruited to join AlleCure Inc. in 2000, and also to MannKind Corp in 2003. In 2017, his pioneering work in the field of IRE-1 inhibitors led directly to first in human clinical trials with the selective IRE1 RNAse inhibitor, ORIN1001. Dr Patterson is cofounded Orinove Inc., and has supported continued collaborations and clinical trials.